titers

[키워드] 95% CI adjusted Admission anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 S1 IgG antibodies antibody antibody levels assigned benefit blinded clinical clinical study clinical trial conducted controlled clinical study convalescent plasma coronavirus disease Coronavirus disease 2019 COVID-19 CP plus standard therapy discharge dose early stage early stages Efficacy Estimated evaluate evaluated Follow-up hospital Hospitalization IgA IgA antibodies IgA antibody IgG increase in intensive care intensive care unit admission less mechanical ventilation Mortality MOST pandemic participant Patient patients per-protocol analysis plasma Primary outcome Primary outcomes Randomized receive reduce reduction reduction in S1 IgG Safe Safety SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2. secondary outcome Secondary outcomes Seven severe coronavirus disease severe COVID-19 ST alone ST group Standard therapy symptoms onset the disease the SARS-CoV-2 the WHO therapeutic option titers transfused transfused plasma transfusion treat Variability variant Viral Viral load viral load reduction was obtained
[DOI] 10.1186/s12879-022-07560-7 PMC 바로가기 [Article Type] Randomized Controlled Trial